Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?

Published: Thu, 8 Nov 2018 12:00:00 EST
Evidence suggests that sacubitril/valsartan may have antiarrhythmic effects. What does this mean for prevention of sudden death?

'Major Breakthrough' in Cystic Fibrosis Treatment

Published: Thu, 18 Oct 2018 11:48:57 EDT
Adding a third drug to modulate the CFTR protein improved respiratory function and reduced sweat chloride concentrations in most patients with cystic fibrosis. Phase 3 trials are ongoing.
Medscape Medical News

Sober Start as Recreational Marijuana Becomes Legal in Canada

Published: Thu, 18 Oct 2018 11:33:36 EDT
Canada became the first industrialized nation to legalize recreational cannabis on Wednesday, but a lawful buzz will be hard to come by in its biggest cities like Toronto and Vancouver, where stores are not yet open.
Reuters Health Information

Novel Anti-B-Cell Therapy Looks Promising in MS

Published: Thu, 18 Oct 2018 11:23:17 EDT
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study.
Medscape Medical News
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Ziopharm’s R&D head joins Spectrum as CMO

Published: Thu, 18 Oct 2018 13:59:55 +0000
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals to serve as its chief medical officer effective Nov. 5.

Gilead, Aelix ally to trial HIV-suppressing combination

Published: Thu, 18 Oct 2018 10:38:27 +0000
Gilead has teamed up with Aelix Therapeutics to trial a combination designed to free people with HIV from the need to take antiretroviral drugs. The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine. 

Novartis inks $2.1B Endocyte buyout, furthering radiotherapy push

Published: Thu, 18 Oct 2018 09:55:05 +0000
Novartis has struck a $2.1 billion (€1.8 billion) deal to acquire Endocyte. The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 million just 12 months ago.

Afferent executives launch next-generation neuro hopeful, gaining Johnson & Johnson backing

Published: Thu, 18 Oct 2018 08:49:18 +0000
CuraSen Therapeutics has pulled off a $54.5 million series A funding round as it gains big-name backing to help tackle neurodegenerative disorders.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy